Ambros Buys Werewolf to Speed Up Drug Approval
A new company, Ambros Therapeutics, formed by buying Werewolf Therapeutics, now works to bring a rare disease drug to patients faster.
A big change happened in the biotech world. Werewolf Therapeutics looked for new ways to move forward. Now, a company called Ambros Therapeutics steps in to help. This move means Ambros bought Werewolf.
Ambros Therapeutics agreed to the deal. It is an all-stock deal. This means Ambros used its own stock to buy Werewolf. Ambros also raised $150 million. This money helps push a key drug through its final tests. This drug treats a rare disease.
The new company, Ambros, will now work to finish the last step for the drug. This step is called Phase 3. It will then ask for approval. This means the drug could soon help many people who have this rare condition.
Source: FierceBiotech
More from Biotech
